RECRUITING

Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

Talk to us

Conditions

StrokeTransient Ischemic Attack (TIA)Personalized medicineCYP2C19minor strokeTransient Ischemic AttackTIA

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.

Official Title

Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing in Patients With Minor Stroke or High Risk TIA (CYP2C19 and Stroke)

Quick Facts

Study Start:2025-04-09
Study Completion:2029-04-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06943586

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 89 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients 18-89 years of age
  2. * admitted to University of Alabama at Birmingham (UAB) main hospital with symptoms or signs of minor ischemic stroke, or high risk TIA
  3. * eligible to receive dual antiplatelet load (presented to the hospital within 66 hours of last known well)
  1. * diagnosis of atrial fibrillation, valvular heart disease, index stroke due to known hypercoagulability (subset of other determined etiology) or large vessel disease (culprit vessel stenosis of ≥50%)
  2. * prescribed anticoagulation prior to stroke
  3. * treated with intravenous thrombolysis
  4. * treated with mechanical thrombectomy
  5. * missing NIH Stroke Scale score

Contacts and Locations

Study Contact

Ekaterina Bakradze, MD
CONTACT
205-975-8569
ebakradze@uabmc.edu
Nita Limdi, PharmD, PhD
CONTACT
205-934-4385
nlimdi@uabmc.edu

Principal Investigator

Ekaterina Bakradze, MD
PRINCIPAL_INVESTIGATOR
University of Alabama at Birmingham

Study Locations (Sites)

University of Alabama at Birmingham
Birmingham, Alabama, 35233
United States

Collaborators and Investigators

Sponsor: University of Alabama at Birmingham

  • Ekaterina Bakradze, MD, PRINCIPAL_INVESTIGATOR, University of Alabama at Birmingham

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-04-09
Study Completion Date2029-04-01

Study Record Updates

Study Start Date2025-04-09
Study Completion Date2029-04-01

Terms related to this study

Keywords Provided by Researchers

  • Personalized medicine
  • CYP2C19
  • minor stroke
  • Transient Ischemic Attack
  • TIA

Additional Relevant MeSH Terms

  • Stroke
  • Transient Ischemic Attack (TIA)